Your shopping cart is currently empty

Z4P, an IRE1 inhibitor with blood-brain barrier permeability (BBB) (IC50=1.13 μM), inhibits glioblastoma growth and recurrence in combination with Temozolomide.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $74 | - | In Stock | |
| 5 mg | $179 | - | In Stock | |
| 10 mg | $297 | - | In Stock | |
| 25 mg | $596 | - | In Stock | |
| 50 mg | $953 | - | In Stock | |
| 100 mg | $1,480 | - | In Stock | |
| 200 mg | $1,980 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $198 | - | In Stock |
| Description | Z4P, an IRE1 inhibitor with blood-brain barrier permeability (BBB) (IC50=1.13 μM), inhibits glioblastoma growth and recurrence in combination with Temozolomide. |
| In vitro | Z4P inhibits IRE1α RNase activity in GBM cells (U87, RADH87, U251, UTMZ), reducing XBP1s and SPARC expression and showing dose-dependent antiproliferative effects. At 25 μM (48 h), Z4P significantly suppresses GBM cell viability and enhances the efficacy of TMZ[1]. |
| In vivo | Z4P crosses the BBB and, at 300 μg/kg i.p. daily for 28 days, significantly reduces tumor size in GBM xenograft mice. Combined with TMZ, Z4P causes near-complete tumor regression with no evident toxicity[1]. |
| Synonyms | Z4-P |
| Molecular Weight | 312.41 |
| Formula | C19H24N2O2 |
| Cas No. | 2361760-87-2 |
| Smiles | O=C(NC1=CC(=CC=C1C)C)NC(C)CCC2=CC=C(O)C=C2 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (256.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (10.56 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.